dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Geynisman, Daniel M. |
dc.contributor.author | Burotto, Mauricio |
dc.contributor.author | Suárez Rodríguez, Cristina |
dc.contributor.author | Bourlon, Maria T. |
dc.contributor.author | Huo, Stephen |
dc.contributor.author | Porta, Camillo |
dc.date.accessioned | 2022-09-09T13:40:26Z |
dc.date.available | 2022-09-09T13:40:26Z |
dc.date.issued | 2022-07 |
dc.identifier.citation | Geynisman DM, Burotto M, Porta C, Suarez C, Bourlon MT, Huo S, et al. Temporal Trends in Grade 3/4 Adverse Events and Associated Costs of Nivolumab Plus Cabozantinib Versus Sunitinib for Previously Untreated Advanced Renal Cell Carcinoma. Clin Drug Investig. 2022 Jul;42:611–622. |
dc.identifier.issn | 1179-1918 |
dc.identifier.uri | https://hdl.handle.net/11351/8126 |
dc.description | Carcinoma de cèl·lules renals avançat; Esdeveniments adversos; Nivolumab |
dc.language.iso | eng |
dc.publisher | Springer |
dc.relation.ispartofseries | Clinical Drug Investigation;42 |
dc.rights | Attribution-NonCommercial 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by-nc/4.0/ |
dc.source | Scientia |
dc.subject | Fetge - Càncer - Tractament |
dc.subject | Quimioteràpia combinada |
dc.subject | Medicaments antineoplàstics - Efectes secundaris |
dc.subject.mesh | Carcinoma, Renal Cell |
dc.subject.mesh | /drug therapy |
dc.subject.mesh | Antineoplastic Combined Chemotherapy Protocols |
dc.title | Temporal Trends in Grade 3/4 Adverse Events and Associated Costs of Nivolumab Plus Cabozantinib Versus Sunitinib for Previously Untreated Advanced Renal Cell Carcinoma |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1007/s40261-022-01170-6 |
dc.subject.decs | carcinoma de células renales |
dc.subject.decs | /farmacoterapia |
dc.subject.decs | protocolos de quimioterapia antineoplásica combinada |
dc.relation.publishversion | https://doi.org/10.1007/s40261-022-01170-6 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Geynisman DM] Department of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA. [Burotto M] Oncology Department, Bradford Hill Clinical Research Center, Santiago, Chile. [Porta C] Interdisciplinary Department of Medicine, University of Bari ‘A.Moro’ and Division of Oncology, A.O.U. Consorziale Policlinico di Bari, Bari, Italy. [Suarez C] Servei d’Oncologia Mèdica, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Bourlon MT] Department of Hemato-Oncology, Urologic Oncology Clinic, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico. [Huo S] Worldwide Health Economics and Outcomes Research-US Market, Bristol Myers Squibb, Princeton, NJ, USA |
dc.identifier.pmid | 35696045 |
dc.identifier.wos | 000810311300001 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |